Enteric NMN Capsule for Intestinal Flora and Mucosal Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively addressed the maintenance of a healthy intestinal mucosal barrier function and balanced enterobacterial flora, which are crucial for overall health, particularly in the face of disruptions caused by Western-style diets and medications like antimicrobial agents and proton pump inhibitors.
Innovation Solution
An enteric capsule formulation containing nicotinamide mononucleotide as an active ingredient, which enhances the barrier function of the intestinal mucosa and balances the enterobacterial flora by modulating the ratios of specific bacterial species, such as decreasing Alistipes and increasing Phascolarctobacterium, while optionally including probiotics and prebiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nicotinamide mononucleotide is administered to improve enterobacterial flora and enhance intestinal mucosal barrier function, then the barrier function and bacterial balance are improved, but the substance may be degraded by gastric acid before reaching the intestine
Solution Approach 1:
The patent uses an enteric capsule as an intermediary delivery system that protects nicotinamide mononucleotide from gastric acid degradation in the stomach and enables controlled release in the intestine, thereby resolving the contradiction between maintaining substance stability and achieving therapeutic effect at the target site
Solution Approach 2:
The patent changes the physical-chemical state of nicotinamide mononucleotide by encapsulating it in an enteric capsule formulation, which alters its resistance to gastric acid and enables pH-dependent release in the intestine, thus protecting the substance while ensuring delivery to the target location
2Reliability
If probiotics and prebiotics are combined with nicotinamide mononucleotide in the enteric capsule formulation, then the effectiveness in improving enterobacterial flora is enhanced, but the device complexity increases
Solution Approach 1:
The patent merges nicotinamide mononucleotide with probiotics and prebiotics into a single enteric capsule formulation, combining multiple functional components that work synergistically to improve enterobacterial flora while maintaining a unified delivery system that manages complexity
Data Source
AI summary
[PROBLEM] To provide a formulation that is safe for ingestion over a long period of time and can improve the enterobacterial flora or can enhance the barrier function of the intestinal mucosa.[SOLUTION] The present invention is an enteric capsule formulation for improving enterobacterial flora containing nicotinamide mononucleotide as an active ingredient.